{"id":"W4415436310","doi":"10.1007/s13555-025-01555-3","title":"Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"melanin and skin pigmentation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"LEO Pharma; Bausch Health; Kyowa Hakko Kirin; Horizon Therapeutics; Incyte; Dermira; Celltrion; Valeant Pharmaceuticals International; Sanofi; Amgen; Meiji Seika Pharma; Pfizer; Concert Pharmaceuticals; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Ruxolitinib; Vitiligo; Clinical trial; Phase (matter); Phases of clinical research","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004354326,0.00008304722,0.0003881682,0.00005810973,0.00001625572,0.000002155514,0.00006116671,0.0001617818,0.00002118448],"category_scores_gemma":[0.00009605977,0.00006092286,0.00005277648,0.00006438633,0.000150062,0.000002786738,0.00001507801,0.00006097319,1.517071e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00000192632,"about_ca_system_score_gemma":0.00005615662,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008235534,"about_ca_topic_score_gemma":0.00001780917,"domain_scores_codex":[0.9986272,0.000475543,0.0006212665,0.0001526256,0.00003815254,0.00008519677],"domain_scores_gemma":[0.999465,0.0001317284,0.0001912655,0.0001270423,0.00006255254,0.00002239325],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005593109,0.001041346,0.9549153,0.00003686786,0.0001524376,0.000003979845,0.00004035027,3.425836e-7,0.008949336,0.0003010822,0.0002046577,0.02876112],"study_design_scores_gemma":[0.02186333,0.001148239,0.700958,0.0001010449,0.00003321327,0.000006668342,0.00007449506,0.00001535249,0.2729566,0.0002042233,0.002507503,0.0001313496],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975813,0.001093165,0.0005877313,0.00005505814,0.00008261995,0.000240321,0.00006647879,0.000002306927,0.0002910375],"genre_scores_gemma":[0.9970236,0.002005626,0.00007363022,0.0002072548,0.000009124416,0.000008634084,0.0006383027,0.000004087571,0.00002978106],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2640073,"threshold_uncertainty_score":0.2484362,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02731667975241602,"score_gpt":0.3794274668762527,"score_spread":0.3521107871238366,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}